On February 7, 2018 Alkermes plc (NASDAQ: ALKS) reported that it will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. GMT) on Wednesday, Feb. 14, 2018, to discuss the company’s fourth quarter and year-end 2017 financial results (Press release, Alkermes, FEB 7, 2018, View Source;p=RssLanding&cat=news&id=2331037 [SID1234523789]). Management will also discuss financial expectations for 2018 and provide an update on the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988.

A replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. GMT) on Wednesday, Feb. 14, 2018, through 5:00 p.m. ET (10:00 p.m. GMT) on Wednesday, Feb. 21, 2018, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.

On February 7, 2018 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, reported that David Hansen, MabVax’s President and Chief Executive Officer will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 11:15 a.m. EST in New York, NY (Press release, MabVax, FEB 7, 2018, View Source [SID1234523784]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of his presentation, Mr. Hansen will provide a corporate overview, including a clinical update on the Company’s two lead clinical development programs: (1) Its fully human antibody therapeutic product, MVT-5873, currently in a Phase 1 clinical study in combination with gemcitabine and nab-paclitaxel in first line therapy for the treatment of newly diagnosed pancreatic cancer patients. The Company remains on track to announce interim safety and response data from the MVT-5873 study early in the first quarter of 2018; and (2) the MVT-1075 program, a human antibody-based radioimmunotherapy ("RIT") product, currently being evaluated in a Phase 1 clinical trial for the treatment of pancreatic, colon and lung cancers. MabVax recently announced the completion of enrollment and dosing of all patients in the initial cohort of the Phase 1 MVT-1075 study and plans to report interim results from this study in the first quarter of 2018.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To schedule a meeting, please contact the Company through the one-on-one meeting portal.

A live audio webcast of the presentation will be available on the Events page of the Investor section of the Company’s website (www.mabvax.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days following the live presentation.

On February 7, 2018 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, will present during the BIO CEO & Investor Conference next week in New York (Press release, Heat Biologics, FEB 7, 2018, View Source [SID1234523783]). Jeff Wolf, CEO of Heat, will present at 9 a.m. ET, on Tuesday, Feb. 13, 2018, and he will also be available to participate in one-on-one meetings with investors registered to attend the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BIO CEO & Investor Forum is a biotech investor conference focused on established and emerging, publicly traded and select private biotech companies. The event features plenary sessions, education sessions focused on therapeutic topics and business issues, company presentations, and one-on-one meetings.

On February 7, 2018 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that the company will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY (Press release, BeiGene, FEB 7, 2018, View Source;p=RssLanding&cat=news&id=2330836 [SID1234523781]). The presentation is scheduled for 9:00 AM ET on Wednesday, February 14, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source An archived replay will be available for 90 days following the event.

On February 7, 2018 AVEO Oncology (NASDAQ: AVEO) reported that Michael Bailey, president and chief executive officer, will present at the following investor conferences (Press release, AVEO, FEB 7, 2018, View Source;p=RssLanding&cat=news&id=2330854 [SID1234523780]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 10:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.

RBC Capital Markets Healthcare Conference on Wednesday, February 21, 2018 at 10:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.

A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.